Taiwan Advanced Nanotech (ROCO:6797) EBITDA: NT$-117.2 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6797 Taiwan Advanced Nanotech Inc ROCO:6797
59 GF Score
Price NT$13.20
GF Value NT$13.40
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Taiwan Advanced Nanotech EBITDA?

Taiwan Advanced Nanotech ROCO:6797 59 EBITDA is NT$-117.2 Mil as of Dec. 2025. GuruFocus rates ROCO:6797 with a GF Score™ of 59/100 and a GF Value™ of NT$13.40 (Fairly Valued). The stock has 4 warning signs investors should review.

Taiwan Advanced Nanotech's EBITDA for the six months ended in Dec. 2025 was NT$-51.4 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-117.2 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Taiwan Advanced Nanotech's EBITDA per Share for the six months ended in Dec. 2025 was NT$-1.69. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-3.83.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

Taiwan Advanced Nanotech  (ROCO:6797) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Taiwan Advanced Nanotech EBITDA Related Terms


Taiwan Advanced Nanotech EBITDA Historical Data

* Premium members only.

The historical data trend for Taiwan Advanced Nanotech's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Advanced Nanotech EBITDA Chart

Taiwan Advanced Nanotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA
Get a 7-Day Free Trial Premium Member Only 881.97 577.40 -114.06 -73.64 -117.15

Taiwan Advanced Nanotech Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.25 -46.29 -27.35 -65.73 -51.42

ROCO:6797 vs ABT, SYK, MDT: EBITDA Comparison

For the Medical Devices subindustry, Taiwan Advanced Nanotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiwan Advanced Nanotech EV-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Taiwan Advanced Nanotech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Taiwan Advanced Nanotech's EV-to-EBITDA falls into.


ROCO:6797
59GF Score
Taiwan Advanced Nanotech Inc ROCO:6797
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Taiwan Advanced Nanotech's EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Taiwan Advanced Nanotech's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2025, Taiwan Advanced Nanotech's EBITDA was NT$-117.2 Mil.

Taiwan Advanced Nanotech's EBITDA for the quarter that ended in Dec. 2025 is calculated as

Taiwan Advanced Nanotech's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2025, Taiwan Advanced Nanotech's EBITDA was NT$-51.4 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-117.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of NT$-117.2 Mil mean?
Taiwan Advanced Nanotech (ROCO:6797) has a EBITDA of NT$-117.2 Mil as of Dec. 2025. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Taiwan Advanced Nanotech.
Is Taiwan Advanced Nanotech's EBITDA too high?
Taiwan Advanced Nanotech's current EBITDA is NT$-117.2 Mil. Overall, Taiwan Advanced Nanotech has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advanced Nanotech's EBITDA compare to ABT and SYK?
Taiwan Advanced Nanotech's EBITDA of NT$-117.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Medical Devices & Instruments company?
A good EBITDA depends on the Medical Devices & Instruments industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Taiwan Advanced Nanotech. Taiwan Advanced Nanotech's current EBITDA is NT$-117.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advanced Nanotech stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advanced Nanotech (ROCO:6797) is currently considered Fairly Valued. The stock's GF Value™ is NT$13.40, compared to a current price of NT$13.20 — trading 1.5% below its estimated fair value. The current EBITDA is NT$-117.2 Mil. Taiwan Advanced Nanotech's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Taiwan Advanced Nanotech (ROCO:6797), the current EBITDA is NT$-117.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiwan Advanced Nanotech (ROCO:6797) Overvalued in 2026?

Based on GuruFocus' analysis, Taiwan Advanced Nanotech stock appears to be undervalued. The current stock price of NT$13.20 is trading 1.5% below its estimated GF Value™ of NT$13.40. GuruFocus considers Taiwan Advanced Nanotech to be Fairly Valued.

Key valuation signals for ROCO:6797:

  • EBITDA: NT$-117.2 Mil
  • GF Value™: NT$13.40 vs. price of NT$13.20 (1.5% below fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6797 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Taiwan Advanced Nanotech Business Description

Address No. 188, Wenhe Road, 6th Floor, Leshan Lane, Guishan District, Taoyuan City, TWN, 330
Taiwan Advanced Nanotech Inc is engaged in development and manufacturing of various functional nanoparticles and automated nucleic acid extraction machines and trading related businesses. With expertise in automation, buffer optimization and modification of magnetic beads, it focuses on offering customer convenient and practical solutions to advance research, life science and molecular diagnostics. It offers various products to meet the requirements of customers. The company's products include Automated Extraction Instruments; Reagent Kit; Mag Nanoparticles; and Consumables.
59GF Score

Get the complete analysis for ROCO:6797

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$13.20
Price
NT$13.40
GF Value